ClinicalTrials.gg
RecruitingNCT07479329PREEATH-T1DUpdated Nov 5, 2026

Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes

An observational study in Type 1 Diabetes, Preeclampsia and Preeclampsia (PE) Risk, sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Recruiting at 2 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,300
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
6th of 36
1,300 · median 170
Started
2026
with 10 others
Observational
36 of 150
8 open now
Primary completion
2028-04
later than 21 of 29 live
Registered
144th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 6th largest by planned enrollment of the 36 observational ones that give a count, is one of 11 that started in 2026, is one of 36 observational ones, reaches primary completion later than 21 of the 29 other live ones, and was the 144th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

This multicenter observational cohort study aims to evaluate whether estimated first-trimester risk of preeclampsia (PE) is associated with subclinical atherosclerosis, cardiovascular risk profile, and cardiovascular events in women with type 1 diabetes (T1D) at least 3 years after pregnancy.

Women with T1D and at least one prior pregnancy with documented first-trimester PE screening will be classified as high or low PE risk according to validated multivariable algorithms. The presence of carotid plaques, cardiometabolic risk factors, and incident cardiovascular events will be assessed during a study visit.

Read the detailed description

Preeclampsia (PE) is associated with increased long-term cardiovascular disease (CVD) risk. Women with type 1 diabetes (T1D) are at particularly high risk of both obstetric and cardiovascular complications.

Although clinical PE has been associated with subclinical carotid atherosclerosis and future cardiovascular events in women with T1D, it is unknown whether estimated first-trimester PE risk identifies a subgroup at increased long-term cardiovascular risk, regardless of the development of clinical PE.

Participants will be women with T1D followed in endocrinology clinics across Spain. Eligible participants must have undergone first-trimester PE screening (\<14 weeks gestation) in at least one pregnancy and be at least 3 years from their last delivery.

The primary exposure variable is first-trimester estimated PE risk (high vs low). Outcomes include subclinical carotid atherosclerosis, cardiometabolic risk profile, and incident cardiovascular events. Secondary outcomes include glycemic metrics from continuous glucose monitoring, cardiovascular health score (Life's Essential 8), patient-reported outcomes, and the effectiveness of aspirin in preventing clinical PE.

Data will be collected in a single study visit using medical records, physical examination, validated questionnaires, and carotid ultrasound (in centers with availability).

03

Conditions studied

  • Type 1 Diabetes
  • Preeclampsia
  • Preeclampsia (PE) Risk

Keywords

  • Type 1 Diabetes
  • Preeclampsia
  • Preeclampsia Risk
  • Preclinical carotid atherosclerosis
  • Carotid ultrasonography
  • Cardiovascular risk
  • Cardiovascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with type 1 diabetes followed in endocrinology clinics who had at least one previous pregnancy with documented first-trimester preeclampsia screening.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Confirmed diagnosis of type 1 diabetes
  • At least one prior pregnancy with first-trimester preeclampsia screening (\<14 weeks gestation)
  • ≥3 years since last pregnancy

Exclusion criteria

Exclusion Criteria:

  • Previous multiple pregnancy
  • Cardiovascular disease before pregnancy (coronary heart disease, stroke/, peripheral artery disease, heart failure)
  • Active pregnancy at time of evaluation
  • Alcohol or substance dependence (except nicotine/caffeine) in the last 3 years
  • Active severe psychiatric disease, dementia, severe disability, or reduced
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,300 participants (estimated)
Patient registry
No

Groups and cohorts

  • High Estimated First-Trimester Preeclampsia Risk

    Women with type 1 diabetes classified as high risk for preeclampsia during first-trimester screening in at least one prior pregnancy.

  • Low Estimated First-Trimester Preeclampsia Risk

    Women with type 1 diabetes classified as low risk for preeclampsia during first-trimester screening in at least one prior pregnancy.

06

What researchers measure

Primary outcomes

  1. Number of carotid plaques

    Presence of focal carotid plaque defined as focal wall thickening ≥1.5 mm detected by standardized 2D carotid ultrasound.

    Time frame: At study visit (≥3 years postpartum)

  2. Hemoglobin A1c (HbA1c)

    HbA1c measured at study visit

    Time frame: At study visit (≥3 years postpartum)

  3. Lipid profile

    Total cholesterol, triglycerides, HDL-cholesterol and Lipoprotein(a) measured directly. LDL-cholesterol estimated using the Friedewald formula.

    Time frame: At study visit (≥3 years postpartum)

  4. Blood pressure

    Systolic blood pressure and diastolic blood pressure.

    Time frame: At study visit (≥3 years postpartum)

  5. Body mass index

    Calculated as weight (in kg) / height (in meters) \^2

    Time frame: At study visit (≥3 years postpartum)

  6. Diabetic-related chronic microvascular complications

    Defined as diabetic retinopathy, chronic kidney disease or diabetic neuropathy

    Time frame: From the last pregnancy to the study visit (≥3 years postpartum)

  7. Incident cardiovascular events

    Composite of coronary artery disease, cerebrovascular disease, peripheral artery disease, or heart failure occurring between last pregnancy and study evaluation.

    Time frame: From last pregnancy to study visit (minimum 3 years)

Secondary outcomes

  1. Carotid intima-media thickness

    Measured by 2D ultrasonography

    Time frame: At study visit (≥3 years postpartum)

  2. Clinical diagnosis of preeclampsia in any pregnancy

    Preeclampsia diagnosis will follow the international criteria (Obstet Gynecol. 2020;135(6):e237-e260)

    Time frame: At study visit (≥3 years postpartum)

  3. Ambulatory glucose profile (continuous glucose monitoring)

    Time-in-range (%), Time-below-range (%), Time-above-range (%), Glucose management indicator (%), Coefficient of variation (%), mean glucose (mg/dL)

    Time frame: Three months prior to study visit

  4. Cardiovascular Health Score

    Assessed using the American Heart Association (AHA) Life's Essential 8. This score ranges from 0 to 100, with higher values indicating better cardiovascular health.

    Time frame: At study visit (≥3 years postpartum)

  5. Patient-reported outcomes. Hypoglycemia Fear Survey (HFS)

    Using the Spanish version of the scale (Tasende C et al. Endocrinol Diabetes Nutr 2018;65:287-296). The score ranges from 24 to 120, with higher values indicating more fear to hypoglycemia.

    Time frame: At study visit (≥3 years postpartum)

  6. Patient-reported outcomes. Clarke Score

    Using the Spanish version of the scale (Jansà M et al. Med Clin 2015;145:511-516). The score ranges from 0 to 7, with higher values indicating less awareness to hypoglycemia.

    Time frame: At study visit (≥3 years postpartum)

  7. Patient-reported outcomes. Diabetes Quality of Life questionnaire (DQoL)

    Using the Spanish version of the scale (Millán MM et al. Endocrinol Nutr. 2002;49:2-8). Higher values indicates better quality of life.

    Time frame: At study visit (≥3 years postpartum)

  8. Patient-reported outcomes. Pittsburgh Sleep Quality Index (PSQI)

    Using the Spanish version of the scale (Royuela A, Macías JA. Psiquis. 1997;18:337-343). The total score ranges from 0 to 21, with a score of 5 or higher indicating poor sleep quality.

    Time frame: At study visit (≥3 years postpartum)

  9. Patient-reported outcomes. Diabetes Distress Scale (DDS)

    Reference: Fisher L et al. J Diabetes Complications 2015;29(4):572-7. Higher scores indicate greater levels of diabetes-related distress.

    Time frame: At study visit (≥3 years postpartum)

  10. Patient-reported outcomes. Problem Areas in Diabetes scale (PAID)

    Using the Spanish version of the scale (Beléndez M et al. Diabetes Research and Clinical Practice. 2014;106: e93-e95). The total score ranges from 0 to 100, with higher scores indicating poor quality of life.

    Time frame: At study visit (≥3 years postpartum)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Mesa A, Puig-Jove C, Pane A, Vinagre I, Lopez-Quesada E, Meler E, Alonso-Carril N, Quiros C, Amor AJ, Perea V. Preeclampsia as an independent predictor of atherosclerosis progression in women with type 1 diabetes: a 5-year prospective study. Cardiovasc Diabetol. 2025 Apr 9;24(1):160. doi: 10.1186/s12933-025-02719-3. PubMed 40205402 ↗
  • Perea V, Vinagre I, Seres-Noriega T, Vinals C, Mesa A, Pane A, Milad C, Esmatjes E, Conget I, Gimenez M, Amor AJ. Impact of Preeclampsia and Parity on Sex-based Discrepancies in Subclinical Carotid Atherosclerosis in Type 1 Diabetes. J Clin Endocrinol Metab. 2024 Aug 13;109(9):e1759-e1767. doi: 10.1210/clinem/dgad755. PubMed 38149646 ↗
  • Amor AJ, Vinagre I, Valverde M, Alonso N, Urquizu X, Meler E, Lopez E, Gimenez M, Codina L, Conget I, Barahona MJ, Perea V. Novel glycoproteins identify preclinical atherosclerosis among women with previous preeclampsia regardless of type 1 diabetes status. Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3407-3414. doi: 10.1016/j.numecd.2021.08.041. Epub 2021 Aug 26. PubMed 34663538 ↗
  • Amor AJ, Vinagre I, Valverde M, Urquizu X, Meler E, Lopez E, Alonso N, Pane A, Gimenez M, Codina L, Conget I, Barahona MJ, Perea V. Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia. Diabetes Res Clin Pract. 2021 Jan;171:108548. doi: 10.1016/j.diabres.2020.108548. Epub 2020 Nov 22. PubMed 33238177 ↗
  • Amor AJ, Vinagre I, Valverde M, Urquizu X, Meler E, Lopez E, Quiros C, Gimenez M, Codina L, Conget I, Barahona MJ, Perea V. Nuclear magnetic resonance lipoproteins are associated with carotid atherosclerosis in type 1 diabetes and pre-eclampsia. Diabetes Metab Res Rev. 2021 Jan;37(1):e3362. doi: 10.1002/dmrr.3362. Epub 2020 Jul 2. PubMed 32515046 ↗
  • Amor AJ, Vinagre I, Valverde M, Pane A, Urquizu X, Meler E, Lopez E, Quiros C, Gimenez M, Codina L, Conget I, Barahona MJ, Perea V. Preeclampsia Is Associated With Increased Preclinical Carotid Atherosclerosis in Women With Type 1 Diabetes. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz031. doi: 10.1210/clinem/dgz031. PubMed 31529047 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to data protection and confidentiality restrictions under the European Union General Data Protection Regulation (EU GDPR 2016/679) and Spanish Organic Law 3/2018 on Personal Data Protection. Although data collected in this study will be coded, the combination of detailed clinical, obstetric, and cardiovascular variables in a relatively specific population (women with type 1 diabetes and prior pregnancy) may pose a potential risk of re-identification. Furthermore, participants provide informed consent for use of their data exclusively for the purposes of this research project and related ethically approved analyses. Data sharing beyond these conditions is not covered by the approved consent framework. Aggregated results will be made publicly available through scientific publications and conference presentations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 18, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Hospital Clínic Barcelona · Barcelona, Spainno status→Recruiting
  • Hospital Universitari Mútua Terrassa · Terrassa, Spainno status→Not yet recruiting
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Hospital Clínic Barcelona · Barcelona, Spainno status→Recruiting
    • Hospital Universitari Mútua Terrassa · Terrassa, Spainno status→Not yet recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479329
Lead sponsor
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Collaborators
Hospital Mutua de Terrassa, Sociedad Española de Endocrinología y Nutrición
Responsible party
Antonio J. Amor (Principal Investigator, Institut d'Investigacions Biomèdiques August Pi i Sunyer) — Principal investigator
First posted
Mar 18, 2026
Start date
Apr 10, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Verónica Perea, MD, PhD
Contact
vperea@mutuaterrassa.cat
+34 93 736 50 50
Antonio J. Amor, MD, PhD
Contact
ajamor@clinic.cat
+34932279846

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion